Innovent Biologics
2000 Alameda de las Pulgas, suite 120
San Mateo
CA
94403
United States
Website: https://www.innoventbio.com/
112 articles with Innovent Biologics
-
Innovent Receives NMPA Breakthrough Designation for IBI310, the Anti-CTLA-4 Monoclonal Antibody, Combined with Sintilimab in Advanced Cervical Cancer Treatment
4/13/2022
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) for IBI310 in combination with sintilimab for the treatment of patients with recurrent or metastatic cervical cancer.
-
Innovent Release Phase 1 Results of IBI322 (anti-PD-L1/CD47 bispecific antibody) in patients with advanced solid tumors at AACR Annual Meeting 2022
4/11/2022
Innovent Biologics, Inc. announced that the results of the Phase I study for IBI322 in patients with advanced solid tumors were presented at the American Association for Cancer Research Annual Meeting 2022.
-
Clinical Catch-Up: COVID-19, AAN, ACC
4/11/2022
It was a very busy week for clinical trial news, in part because of presentations coming out of the American Academy of Neurology (AAN) meeting. Here’s a look. -
Innovent Announces the Approval of Pemazyre® (pemigatinib) by the NMPA for the Treatment of Adults with Locally Advanced or Metastatic Cholangiocarcinoma
4/6/2022
Innovent Biologics, Inc. announced that the National Medical Products Administration (NMPA) has approved Pemazyre.
-
Innovent Releases Results of a Phase 3 Clinical Study of IBI306 (PCSK-9 inhibitor) in Chinese Patients with Heterozygous Familial Hypercholesterolemia at the American College of Cardiology Annual Congress 2022
4/4/2022
Innovent Biologics, Inc. announces that the results of a phase 3 clinical trial of recombinant full-human anti-PCSK-9 monoclonal antibody in Chinese patients with heterozygous familial hypercholesterolemia have been accepted as an abstract presented at the American College of Cardiology Annual Congress 2022.
-
Innovent Announces First Patient Dosing of Claudin18.2/CD3 Bispecific Antibody IBI389 in Phase 1a/1b Clinical Trial for Advanced Solid Tumor
3/29/2022
Innovent Biologics, Inc. announced the first patient dosing for its proprietary recombinant bispecific antibody targeting Claudin18.2 and CD3 in a Phase I clinical trial for the treatment of advanced malignancies.
-
Innovent Announced 2021 Annual Results
3/29/2022
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases announced 2021 annual results including its major achievements and progress.
-
Innovent and Lilly Expand Strategic Partnership in Oncology
3/28/2022
Innovent Biologics, Inc. and Eli Lilly and Company announced that in light of both parties' shared commitment to continue bringing innovative medicines to benefit Chinese patients and to leverage the strengths of each party in a win-win manner, parties will now expand the strategic partnership through:
-
The U.S. Food and Drug Administration rejected Eli Lilly’s Biologics License Application, issuing a Complete Response Letter for the company’s PD-1 checkpoint inhibitor sintilimab.
-
China has become a leader in biotech in the last five years, especially in CAR-T therapies. Companies like Johnson & Johnson are on the prowl to acquire Chinese companies to form collaborations.
-
AnHeart Therapeutics and Innovent Biologics Receive NMPA Breakthrough Designation for Taletrectinib in ROS1 Fusion-Positive Non-Small Cell Lung Cancer
3/1/2022
AnHeart Therapeutics (“AnHeart”), together with Innovent Biologics, Inc. (“Innovent”, HKEX: 01801), today jointly announce that the Center for Drug Evaluation (CDE) of China’s Nation Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) to taletrectinib.
-
Innovent Biologics and AnHeart Therapeutics Receive NMPA Breakthrough Designation for Taletrectinib in ROS1-Positive Non-Small Cell Lung Cancer
2/28/2022
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), together with AnHeart Therapeutics ("AnHeart"), today jointly announced that the Center for Drug Evaluation (CDE) of China's Nation Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) to taletrectinib.
-
The FDA places holds, companies receive clearance for new studies and Pharma giants release new data in last week's clinical trial news.
-
Innovent Announces First Patient Dosed with CD73 Antibody in Phase 1a/1b Clinical Trial for Advanced Solid Tumor
2/23/2022
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), today announces that the first patient has been successfully dosed in the phase 1, first-in-human clinical trial of its proprietary CD73 antibody (development code: IBI325) in patients with advanced solid tumor.
-
Innovent Announces First Patient Dosing of Universal "Modular" CAR-T Cell product IBI345
2/21/2022
Innovent Biologics, Inc. announced the first patient dosing for its first-in-class IgG-based universal "modular" Claudin 18.2-targeting chimeric antigen receptor T cell product for the treatment of advanced Claudin18.2-positive solid tumors in an investigator-initiated-trial.
-
By the end of the CREDIT-1 study, patients experienced a significant reduction in low-density lipoprotein cholesterol compared to the placebo group.
-
Innovent Announces Two Registration Studies of IBI306 (anti-PCSK-9 antibody) Met Primary Endpoint
2/16/2022
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), announces that the primary endpoint was met in two Chinese registration studies of recombinant full-human anti-PCSK-9 monoclonal antibody.
-
The unspoken challenge is: how diverse can a trial run in the United States really be right now?
-
U.S. FDA Grants Orphan Drug Designation to BCMA CAR-T Cell Therapy Co-Developed by IASO Bio and Innovent
2/14/2022
IASO Biotherapeutics and Innovent Biologics, Inc. jointly announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration has granted Orphan Drug Designation to their fully human anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy for the treatment of relapsed and/or refractory multiple myeloma.
-
U.S. FDA Grants Orphan Drug Designation to BCMA CAR-T Cell Therapy Co-Developed by Innovent and IASO Bio
2/14/2022
Innovent Biologics, Inc. together with IASO Biotherapeutics jointly announced that the U.S. Food and Drug Administration's Office of Orphan Products Development has formally granted Orphan Drug Designation to their co-developed fully-human B-cell maturation antigen -targeted chimeric antigen receptor T-cell therapy for the treatment of patients with relapsed/refractory multiple myeloma.